Senior insider sale
EVP of R&D at ALLOGENE THERAPEUTICS, INC. — senior position signals high conviction
$40.9K
26.27K shares
What this filing means
ROBERTS ZACHARY plans to sell 26.27K shares of ALLOGENE THERAPEUTICS, INC. valued at approximately $40.9K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 1/21/2026ACC: 0001851044-26-000001
Officer· EVP of R&D
Since Feb 2026
26.27K
Shares to sell
$40.9K
Approx. market value
26.27K
Acquired (3 months)
1
Planned
Securities Acquired — Last 3 Months1
Vesting of restricted stock unit award
Granted as part of issuer equity compensation plan
1/20/2026
26.27KTotal acquired26.27K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
1/20/2026 | Vesting of restricted stock unit award Granted as part of issuer equity compensation plan | 26.27K | — |
| Total | 26.27K | ||
Planned & Completed Dispositions1
NASDAQPlanned
Units to sell
26.27K
Market value
$40.9K
1/21/2026
Total
Units
26.27K
Value
$40.9K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
1/21/2026 | 26.27K | $40.9K | NASDAQ | Planned |
| Total | 26.27K | $40.9K | ||